All Videos
Verona Pharma
Ensifentrine
Dr Kathleen Rickard, MD, Chief Medical Officer, Verona Pharma discusses the burden of COPD and urgent need for a novel treatment.
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD.
About Us
Patients
Media
Contact
Stock Information
News & SEC Filings
Events & Presentations
Financial Results
Shareholder Information
Analyst Coverage
© Verona Pharma plc 2023. All rights reserved
